Premium
Monitoring of modified factor VIII and IX products
Author(s) -
Kitchen S.,
Gray E.,
Mertens K.
Publication year - 2014
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/hae.12423
Subject(s) - medicine , session (web analytics) , factor ix , potency , factor (programming language) , computational biology , computer science , biochemistry , world wide web , biology , in vitro , programming language
Summary The dawning era of novel recombinant factor VIII and factor IX concentrates, many of which have been bioengineered to achieve prolonged activity, brings with it the need to consider the most appropriate clinical laboratory approaches for potency assignment, as well as the measurement of postinfusion levels. This session will highlight the known limitations and inconsistencies between existing assay methodologies with respect to currently available products, and discuss some of the early data with respect to the novel agents.